摘要
随着抗菌药物耐药现象的加剧，建立和完善药敏试验标准是获得准确的药敏结果，进而实现临床个体化治疗的前提。CLSI制定的药敏试验标准是我国临床实验室遵循的指导性文件，其每年更新的内容引起微生物工作者的广泛重视。本文将重点解读2015年CLSIM100-S25新增的CarbaNP确证试验和流行病学cut-off值的概念，同时介绍其他主要更新，以供同行参考。
Drug resistance is becoming a serious issue worldwide. Obtaining accurate antimicrobial susceptibility results requires refined standard operation procedures, thus achieving the goal of individual therapy. The interpretive criteria CLSI revised annually causes widespread concern of clinical microbiologists. The major changes in CLSI M100-S25 are described in this article, focusing on the introduction of Carba NP confirmatory test for suspected carbapenemase production and epidemiological, cutoff values.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2015年第4期229-232,共4页
Chinese Journal of Laboratory Medicine
关键词
抗菌药
微生物敏感性试验
质量控制
Anti-bacterial agents
Microbial sensitivity tests
Quality control
作者简介
通信作者：王辉，电子信箱：whuibj@163．com
